Previously, we evaluated the feasibility of specifically enhancing the delivery of a PSMA-targeted MNP to PSMA(+) tumors in a preclinical dual PSMA(+) and PSMA(-) human prostate tumor mouse model, with high tumor vascular permeability 52. This evidence concerns the gene FOLH1 and prostate neoplasm.